{
    "clinical_study": {
        "@rank": "77374", 
        "arm_group": {
            "arm_group_label": "DESolve Novolimus Eluting Bioresorbable Coronary Scaffold", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety, performance and efficacy of the Elixir DESolve\u00ae Novolimus Eluting\n      Bioresorbable Coronary Scaffold System (BCSS) in patients with a single de novo native\n      coronary artery lesion designated the target lesion and up to one non-target lesion located\n      in a separate epicardial vessel."
        }, 
        "brief_title": "Elixir Medical Clinical Evaluation of the DESolve\u00ae Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be at least 18 years of age and for the 35-patient subset, patients must\n             be over the age of 50\n\n          -  Patient is able to verbally confirm understanding of risks, benefits and treatment\n             alternatives of receiving the DESolve Nx Novolimus Eluting BCSS and he/she provides\n             written informed consent, as approved by the appropriate Ethics Committee of the\n             respective clinical site, prior to any clinical study related procedure\n\n          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,\n             silent ischemia, positive functional study or electrocardiogram (ECG) changes\n             consistent with ischemia)\n\n          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)\n             surgery\n\n          -  Patient must agree to undergo all clinical study required follow-up visits,\n             angiograms, and as applicable, IVUS, OCT, MSCT and coronary vasomotion testing\n\n          -  Patient must agree not to participate in any other clinical study for a period of two\n             years following the index procedure\n\n        Angiographic Inclusion Criteria:\n\n        Target lesion must be located in a native coronary artery with a nominal vessel diameter\n        of between 2.75 and 3.5 mm assessed by online QCA\n\n          -  Target lesion must measure \u2264 14 mm in length\n\n          -  Target lesion must be in a major artery or branch with a visually estimated stenosis\n             of \u2265 50% and < 90% with a TIMI flow of \u2265 1\n\n          -  Percutaneous intervention of lesions in the target vessel if:\n\n               1. Not part of a clinical investigation\n\n               2. \u2265 6 months prior to the study index procedure\n\n               3. \u2265 9 months after the study index procedure (planned)\n\n               4. Previous intervention was distal to and >10mm from the target lesion\n\n        Exclusion Criteria:\n\n          -  Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours\n             preceding the index procedure and CK and CK-MB have not returned within normal limits\n             at the time of procedure\n\n          -  Patient is currently experiencing clinical symptoms consistent with AMI\n\n          -  Patient requires the use of any rotablator intervention during the index procedure\n\n          -  Patient has current unstable arrhythmias\n\n          -  Patient has a known left ventricular ejection fraction (LVEF) < 30%\n\n          -  Patient has received a heart transplant or any other organ transplant or is on a\n             waiting list for any organ transplant\n\n          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30\n             days prior to or after the procedure\n\n          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or\n             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus\n             etc.)\n\n          -  Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that\n             cannot be stopped and restarted according to local hospital standard procedures.\n\n          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and\n             bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast\n             sensitivity that cannot be adequately pre-medicated\n\n          -  Elective surgery is planned within the first 6 months after the procedure that will\n             require discontinuing either aspirin or clopidogrel\n\n          -  Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of <\n             3,000 cells/mm3, or documented or suspected liver disease.\n\n          -  Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5\n             mg/dL, or patient on dialysis)\n\n          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood\n             transfusions\n\n          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological\n             attack (TIA) within the past six months\n\n          -  Patient has had a significant GI or urinary bleed within the past six months\n\n          -  Patient has extensive peripheral vascular disease that precludes safe 6 French sheath\n             insertion\n\n          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known\n             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause\n             non-compliance with the clinical study plan, confound the data interpretation or is\n             associated with a limited life expectancy (i.e., less than one year)\n\n          -  Patient is already participating in another clinical study\n\n          -  Women of childbearing potential who have not undergone surgical sterilization or are\n             not post-menopausal (defined as amenorrheic for at least one year) as well as women\n             who are pregnant or nursing\n\n          -  Patient is unable to give their consent, is legally incompetent, or is\n             institutionalized by virtue of an order issued by the courts or other authority\n\n        Angiographic Exclusion Criteria\n\n          -  Target lesion(s) meets any of the following criteria:\n\n               1. Aorto-ostial location\n\n               2. Left main location\n\n               3. Located within 5 mm of the origin of the LAD or LCX\n\n               4. Located within an arterial or saphenous vein graft or distal to a diseased\n                  arterial or saphenous vein graft\n\n               5. Lesion involving a side branch >2mm in diameter or bifurcation\n\n               6. Previous placement of a scaffold proximal to or within 10 mm of the target\n                  lesion\n\n               7. Total occlusion (TIMI flow 0), or TIMI flow < 1\n\n               8. Excessive tortuosity proximal to or within the lesion\n\n               9. Angulation (\u2265 45o) proximal to or within the lesion\n\n              10. Calcification moderate or heavy\n\n              11. Previous intervention restenosis\n\n          -  The target vessel contains visible thrombus\n\n          -  Another clinically significant lesion (>40%) is located in the same major epicardial\n             vessel as the target lesion\n\n          -  Patient has a high probability that a procedure other than pre-dilatation and\n             scaffolding and (if necessary) post-dilatation will be required at the time of index\n             procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon or\n             brachytherapy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086045", 
            "org_study_id": "ELX-CL-1003"
        }, 
        "intervention": {
            "arm_group_label": "DESolve Novolimus Eluting Bioresorbable Coronary Scaffold", 
            "intervention_name": "DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Coronary artery disease", 
        "lastchanged_date": "March 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Antwerp", 
                        "country": "Belgium", 
                        "zip": "2020"
                    }, 
                    "name": "AZ Middelheim Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "B-3600"
                    }, 
                    "name": "St. - Jan Ziekenhuis Z.O.L."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "zip": "0401210"
                    }, 
                    "name": "Instituto Dante Pazzanese"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uberlandia", 
                        "country": "Brazil", 
                        "zip": "38400-368"
                    }, 
                    "name": "ICT / Instituto Do Coracao Do Triangulo Mineiro"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aarhus N", 
                        "country": "Denmark", 
                        "zip": "8200"
                    }, 
                    "name": "Aarhus University Hospital, Skejby"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12203"
                    }, 
                    "name": "Charite - Campus Benjamin Franklin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22527"
                    }, 
                    "name": "Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1023"
                    }, 
                    "name": "Auckland City Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1023"
                    }, 
                    "name": "Mercy Angiography Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "0622"
                    }, 
                    "name": "North Shore Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u0105browa G\u00f3rnicza", 
                        "country": "Poland", 
                        "zip": "43-300"
                    }, 
                    "name": "Polsko-Ameryka\u0144skie Kliniki Serca"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-501"
                    }, 
                    "name": "Jagiellonian University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-202"
                    }, 
                    "name": "Centrum Interwencyjnego Leczenia Chor\u00f3b Serca"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Brazil", 
                "Denmark", 
                "Germany", 
                "New Zealand", 
                "Poland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve\u00ae NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS", 
        "other_outcome": [
            {
                "description": "Acute Success is classified according to the following definitions:\nProcedure success - Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis of < 50% by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of ischemia driven major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days post index procedure.", 
                "measure": "Acute success - Procedure success", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Acute Success is classified according to the following definitions:\nDevice success - Successful delivery and deployment of the Clinical Investigation scaffold at the target lesion and successful withdrawal of the scaffold delivery system with attainment of final residual stenosis < 50% by QCA (by visual estimation if QCA is unavailable). Standard pre-dilation catheters and post-dilatation catheters (if applicable) may be used. Bailout subjects will be included as device success only if the above criteria for clinical device success are met.", 
                "measure": "Acute success - Device success", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Instituto Dante Pazzanese de Cardiologia", 
                "last_name": "Alex Abizaid, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AZ Middelheim Hospital", 
                "last_name": "Stefan Verheye, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Auckland City Hospital", 
                "last_name": "John Ormiston, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum", 
                "last_name": "Joachim Schofer, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "New Zealand: Ethics Committee", 
                "Poland: Ethics Committee", 
                "Poland: Ministry of Health", 
                "Germany: Ethics Commission", 
                "Belgium: Ethics Committee", 
                "Belgium: Federal Agency for Medicinal Products and Health Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Clinically-indicated major adverse cardiac events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Clinically-indicated major adverse cardiac events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "6 month"
            }, 
            {
                "measure": "Clinically-indicated major adverse cardiac events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "12 month"
            }, 
            {
                "measure": "Clinically-indicated major adverse cardiac events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinically-indicated major adverse cardiac events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinically-indicated major adverse cardiac events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Clinically-indicated major adverse cardiac events (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinically-Indicated Target Lesion Failure (TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "- Minimum Lumen Diameter (MLD) and % DS post procedure", 
                "measure": "In-scaffold Late Lumen Loss", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "description": "- Proximal and Distal Late Lumen Loss", 
                "measure": "In-scaffold Late Lumen Loss", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "- In-lesion Late Lumen Loss", 
                "measure": "In-scaffold Late Lumen Loss", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "- In-scaffold and in-lesion Angiographic Binary Restenosis (ABR) (\u2265 50%)", 
                "measure": "In-scaffold Late Lumen Loss", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "- In-scaffold and in-lesion % Diameter Stenosis", 
                "measure": "In-scaffold Late Lumen Loss", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Elixir Medical Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elixir Medical Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}